Daily Archives: July 22, 2016

The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment week 12 (SVR12) in noncirrhotic patients infected with hepatitis C virus (HCV) genotypes (GTs) 1… Continue reading →

Celiac disease has been an outlier among intestinal diseases. Although not as prevalent as irritable bowel syndrome, it is significantly more common than inflammatory bowel disease.1 Although patients are rarely hospitalized or undergo surgery due to c… Continue reading →

The Health Resources and Services Administration (HRSA), an agency of the United States Department of Health and Human Services identified fair access and reduction of geographic disparities as the top priorities in the Organ Procurement and Transplan… Continue reading →

The rapid development of new treatments for hepatitis C virus (HCV) has truly been astonishing over the last 3 years with the introduction of all oral direct-acting antivirals (DAAs). Multiple therapeutic regimens are now available for patients depending on viral genotype.1–6 Although no comparative studies exist between regimens, all have very similar overall sustained virologic response (SVR) rates of >95% in a broad range of patients, with the best response in genotype 1 compared with genotypes 2 and 3. Continue reading →

Gruber et al1 demonstrate that YAP/TAZ activity is critical for acinar ductal metaplasia (ADM) by crossing conditional knock-out mice with the well-studied LSL-Kras model of PDAC. They also provide evidence that YAP/TAZ may be sufficient, because ecto… Continue reading →

In this issue of Gastroenterology Chang et al1 from Taiwan describe further outcomes of one of the seismic events in the history of hepatology, namely hepatitis B vaccination. There have been several of these seismic events that have and will continue… Continue reading →